New antibody drug aims to block brain attacks in autoimmune encephalitis
NCT ID NCT06575153
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug called ART5803 in 64 healthy adults to see if it is safe. ART5803 is a lab-made antibody designed to block harmful immune proteins that attack the brain in autoimmune encephalitis. The study gave single or multiple doses and compared them to a placebo, focusing on safety and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ART5803 (a lab-made antibody that blocks harmful immune attacks on brain cells)
What this could lead to
If safe, this could lead to a treatment that stops the immune system from attacking the brain in autoimmune encephalitis, potentially controlling the disease.
What could go wrong
This is an early Phase 1 safety study in only 64 healthy people, not patients. It does not test if the drug works for the disease, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia